Tesamorelin: Discovery & Research History
Tesamorelin (GHRH Analog) — how it was originally discovered, and what it has been studied for since.
How Tesamorelin Was Discovered
Tesamorelin has a more specific origin story than most peptides in this catalogue: it was developed by the Montreal-based company Theratechnologies with one particular research problem in mind. In the late 1990s, HIV-associated lipodystrophy — a disfiguring redistribution of body fat, often involving excess visceral abdominal fat, caused as a side effect of antiretroviral therapy — had become a significant and clinically distressing problem for people living with HIV. Theratechnologies engineered Tesamorelin as a stabilized analog of GHRH(1-44), the naturally occurring growth-hormone-releasing hormone, specifically to research this condition.
That targeted research program led to Tesamorelin becoming the one peptide in this catalogue with a specific, named drug approval: the U.S. FDA approved it under the brand name Egrifta on November 10, 2010, as the first FDA-approved treatment for HIV-associated lipodystrophy, marketed in the United States by EMD Serono. The compound's clinical relevance hasn't stood still since — in March 2025, the FDA approved an updated formulation, Egrifta WR (tesamorelin F8), which moved from a daily to a weekly reconstitution schedule.
It's worth being precise about what that approval covers: it applies to the pharmaceutical product Egrifta, for a specific clinical indication, under prescription and medical supervision. KYIN's Tesamorelin is sold strictly for laboratory research use, not as an approved drug, and is not intended for human or animal use.
What Tesamorelin Has Been Studied For
Tesamorelin's research applications continue to center on the growth-hormone and lipid-metabolism mechanisms its original development program targeted.
- Growth hormone regulation research
- Lipid metabolism studies
- Visceral adiposity research models
Tesamorelin discovery & history questions
Does Tesamorelin's research history mean it's approved for a particular use?
No. This page describes how Tesamorelin was originally discovered and what it has been studied for since — it is historical and educational context, not a claim about current regulatory approval, safety, or legal status anywhere. KYIN Peptides sells Tesamorelin strictly for laboratory research use.
What has Tesamorelin been studied for in research?
Tesamorelin is most commonly studied in growth hormone regulation research, lipid metabolism studies, and visceral adiposity research models.
Looking for Tesamorelin specs and pricing?
View purity, available sizes, and pricing on the product page.